Therapeutic development spans the entire journey from drug discovery to final approval for commercialization, with each stage requiring rigorous experimental validation and regulatory scrutiny. Our company offers a comprehensive array of services and integrated drug development platforms to expedite therapeutic development for rare gastrointestinal diseases.

Overview of Therapeutic Development

Rare gastrointestinal diseases often lack effective therapeutic options due to a limited understanding of their underlying mechanisms and a narrower research focus. It is imperative to develop therapies for these diseases to address the substantial unmet needs of individuals grappling with these conditions.

The advancements in biologics and gene therapies have unveiled novel avenues for treating rare gastrointestinal diseases. For instance, GLP-2 analogs are under investigation for potential application in various rare gastrointestinal disorders, with the degradation-resistant GLP-2 analog teduglutide already approved for managing short bowel syndrome-intestinal failure.

Fig.1 Main biological actions of GLP-1 and GLP-2 in gastrointestinal diseases. (Kounatidis, D., et al., 2022)

Developing therapeutics for rare gastrointestinal diseases involves a systematic and interdisciplinary approach geared toward identifying and advancing effective therapeutics for these infrequent and intricate conditions. The following are the key steps in the developmental process:

• Target Identification
  It is identifying specific molecular targets or pathways implicated in the rare gastrointestinal disease process that could serve as potential targets for therapeutic intervention.

• Drug Discovery and Development
  Screening potential drug candidates capable of modulating the identified targets. Optimizing lead compounds to improve their efficacy, safety, and pharmacokinetic properties.

• Therapeutic Evaluation
  Performing in vitro and in vivo studies to evaluate the pharmacokinetics, pharmacodynamics, and potential toxicities of the drug candidates in cell-based, organoid, and animal models.

Our Services

Our team comprises researchers and industry professionals committed to expediting the discovery and development of innovative therapies for rare gastrointestinal diseases, ensuring the swift and efficient translation of scientific breakthroughs. With the rapid advancements in technology, our company has established a robust therapeutic development process system to offer comprehensive solutions throughout the drug development journey, encompassing target identification, therapeutic discovery, and disease model development for in vitro and in vivo therapeutic assessments.

Diversified Therapeutic Development Platform

Small Molecule Drug

Therapeutic Antibody

Diverse Platforms

Cell Therapy

Therapeutic Peptide

Gene Therapy

Therapeutic Protein

Microbiome Therapeutic

Focus on Multiple Rare Gastrointestinal Disease

Utilizing state-of-the-art research, pioneering technologies, and a multidisciplinary approach, we specialize in providing therapeutic development services tailored for rare gastrointestinal diseases to ultimately enhance outcomes for individuals grappling with these complex conditions. If you are interested in our services, please do not hesitate to reach out to us for further information.

Reference

• Kounatidis, Dimitris et al. "Therapeutic Potential of GLP-2 Analogs in Gastrointestinal Disorders: Current Knowledge, Nutritional Aspects, and Future Perspectives." Current nutrition reports 11.4 (2022): 618-642.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.